It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Purine nucleotides are necessary for various biological processes related to cell proliferation. Despite their importance in DNA and RNA synthesis, cellular signaling, and energy-dependent reactions, the impact of changes in cellular purine levels on cell physiology remains poorly understood. Here, we find that purine depletion stimulates cell migration, despite effective reduction in cell proliferation. Blocking purine synthesis triggers a shunt of glycolytic carbon into the serine synthesis pathway, which is required for the induction of cell migration upon purine depletion. The stimulation of cell migration upon a reduction in intracellular purines required one-carbon metabolism downstream of de novo serine synthesis. Decreased purine abundance and the subsequent increase in serine synthesis triggers an epithelial-mesenchymal transition (EMT) and, in cancer models, promotes metastatic colonization. Thus, reducing the available pool of intracellular purines re-routes metabolic flux from glycolysis into de novo serine synthesis, a metabolic change that stimulates a program of cell migration.
Nucleotides are essential for different biological processes and have been also associated to cancer development. Depleting cellular nucleotides is a strategy commonly employed to target cancers. Here, the authors show that purine depletion induces serine synthesis to promote cancer cell migration and metastasis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Texas Southwestern Medical Center, Children’s Medical Center Research Institute, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
2 Feinberg School of Medicine, Northwestern University, Department of Biochemistry and Molecular Genetics, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507); Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
3 University Hospital Essen & German Cancer Consortium, Partner Site, Department of Dermatology, Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331)
4 Harvard T. H. Chan School of Public Health, Department of Molecular Metabolism, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
5 Metabolomics Core Facility, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, USA (GRID:grid.16753.36) (ISNI:0000 0001 2299 3507)
6 Mass Spectrometry Core, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547)